Hamlin P, Farber C, Fenske T, et al. The dual SYK/JAK inhibitor cerdulatinib demonstrates complete inhibition of SYK and JAK and rapid tumor responses in a phase 2 study in patients with relapsed/refractory B cell malignancies. EHA 2017, abstract S773.
Versnippering van systemische oncologische zorg
nov 2023 | Borstkanker, Bot en wekedelentumoren, Chirurgie, Dermato-oncologie, Gynaecologische oncologie, Hoofd-halsoncologie, Immuuntherapie, Longoncologie, Maag-darm-leveroncologie, Mesothelioom, Neuro-oncologie, Uro-oncologie